Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parotid Oncocytomas Express the Glycoprotein Non-metastatic Melanoma Protein B (GPNMB): A Potential Link with Birt-Hogg-Dubé Syndrome.

Head and neck pathology·2026
Same author

Closing the epidemiologic gap in keloid disease: A call to action for investigative dermatology.

The Journal of investigative dermatology·2026
Same author

Basaloid adenosquamous carcinoma mimicking adenoid cystic carcinoma (BAC MAC): A novel subtype of head and neck squamous cell carcinoma.

Annals of diagnostic pathology·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

Characterization of the urinary DNA virome of hematopoietic stem cell transplant recipient and healthy cynomolgus macaques.

bioRxiv : the preprint server for biology·2026
Same author

A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.

Liver cancer·2026

Related Experiment Video

Updated: May 26, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.

Dong-Min Yu, Eunice Lee, Gabriel J Starrett

    Biorxiv : the Preprint Server for Biology
    |May 25, 2026
    PubMed
    Summary

    Researchers discovered low-frequency IDH1/2 mutations in sporadic angiosarcoma, driving tumor growth. The targeted therapy ivosidenib showed significant tumor regression in patients with these mutations, offering a new treatment strategy.

    More Related Videos

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    Comparative Lesions Analysis Through a Targeted Sequencing Approach
    08:16

    Comparative Lesions Analysis Through a Targeted Sequencing Approach

    Published on: November 5, 2019

    Related Experiment Videos

    Last Updated: May 26, 2026

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
    06:27

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

    Published on: May 9, 2025

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    Comparative Lesions Analysis Through a Targeted Sequencing Approach
    08:16

    Comparative Lesions Analysis Through a Targeted Sequencing Approach

    Published on: November 5, 2019

    Area of Science:

    • Oncology
    • Genetics
    • Molecular Biology

    Background:

    • The genetic causes of sporadic angiosarcoma are not well understood.
    • Maffucci syndrome, linked to IDH1/2 mutations, involves vascular tumors, but these mutations were previously unreported in sporadic angiosarcoma.

    Purpose of the Study:

    • To investigate the genetic underpinnings of sporadic angiosarcoma.
    • To explore the therapeutic potential of targeting IDH1/2 mutations in angiosarcoma.

    Main Methods:

    • Whole-exome sequencing to identify mutations.
    • Sanger sequencing and immunohistochemistry for validation.
    • In vitro studies on mutant IDH1 endothelial cells.
    • Clinical assessment of ivosidenib treatment response.

    Main Results:

    • Recurrent, low-variant allele frequency hotspot mutations in IDH1/2 were found in over half of sporadic angiosarcomas.
    • Mutant IDH1 promotes tumorigenesis via non-cell-autonomous mechanisms, including 2-hydroxyglutarate secretion.
    • Ivosidenib reversed these pro-tumorigenic effects in vitro and led to significant tumor regression in patients.

    Conclusions:

    • Subclonal IDH1/2 mutations are a significant driver of sporadic angiosarcoma.
    • Ivosidenib is a promising targeted therapy for angiosarcomas with low-VAF IDH1/2 mutations.
    • Targeting IDH1/2 mutations represents a novel therapeutic vulnerability in vascular tumors.